| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
94,670,000 |
| Market
Cap: |
90.88(M) |
| Last
Volume: |
940,193 |
Avg
Vol: |
714,677 |
| 52
Week Range: |
$0.754 - $7.66 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Assertio Therapeutics is a pharmaceutical company. Co.'s primary marketed products include: INDOCIN® (indomethacin) Suppositories and INDOCIN® (indomethacin) Oral Suspension, which is a suppository form and oral solution of indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), approved for moderate to severe rheumatoid arthritis, ankylosing spondylitis and osteoarthritis; CAMBIA® (diclofenac potassium for oral solution), which is a prescription NSAID indicated for the acute treatment of migraine attacks in adults; and Otrexup® (methotrexate) injection, used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2013-12-02 |
4 |
AS |
$8.40 |
$35,878 |
D/D |
(4,270) |
9,084 |
|
- |
|
| Gosling Matthew M |
Senior VP, General Counsel |
• – – |
2013-12-02 |
4 |
AS |
$8.40 |
$47,836 |
D/D |
(5,692) |
11,396 |
|
- |
|
| Moretti August J |
Chief Financial Officer |
• – – |
2013-12-02 |
4 |
AS |
$8.40 |
$23,709 |
D/D |
(2,821) |
11,214 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2013-10-15 |
4 |
OE |
$6.50 |
$97,500 |
D/D |
15,000 |
40,000 |
|
- |
|
| Moretti August J |
Chief Financial Officer |
• – – |
2013-05-17 |
4 |
OE |
$5.35 |
$13,375 |
D/D |
2,500 |
3,752 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2013-05-10 |
4 |
B |
$5.11 |
$127,633 |
D/D |
25,000 |
85,001 |
2.81 |
- |
|
| Dawes Karen A |
Director |
– • – |
2013-03-06 |
4 |
B |
$5.96 |
$11,920 |
D/D |
2,000 |
8,000 |
2.39 |
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2013-03-04 |
4 |
OE |
$1.83 |
$16,013 |
D/D |
8,750 |
47,619 |
|
- |
|
| Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2012-12-13 |
4 |
S |
$5.87 |
$256,024 |
D/D |
(43,635) |
1,680 |
|
- |
|
| Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2012-12-13 |
4 |
OE |
$1.83 |
$73,200 |
D/D |
40,000 |
45,315 |
|
- |
|
| Gosling Matthew M |
Senior VP, General Counsel |
• – – |
2012-12-12 |
4 |
AS |
$5.84 |
$383,851 |
D/D |
(65,702) |
0 |
|
- |
|
| Gosling Matthew M |
Senior VP, General Counsel |
• – – |
2012-12-12 |
4 |
OE |
$3.09 |
$148,706 |
D/D |
48,125 |
65,702 |
|
- |
|
| Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2012-12-06 |
4 |
AS |
$5.77 |
$8,175 |
D/D |
(1,418) |
5,315 |
|
- |
|
| Gosling Matthew M |
Senior VP, General Counsel |
• – – |
2012-12-06 |
4 |
AS |
$5.80 |
$15,168 |
D/D |
(2,615) |
17,578 |
|
- |
|
| Stern Julian N |
Director |
– • – |
2012-12-05 |
4 |
OE |
$1.95 |
$29,250 |
D/D |
15,000 |
208,333 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2012-08-14 |
4 |
B |
$5.01 |
$25,049 |
I/I |
5,000 |
25,000 |
2.1 |
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2012-08-09 |
4 |
OE |
$1.83 |
$24,019 |
D/D |
13,125 |
36,799 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2012-08-07 |
4 |
OE |
$1.49 |
$22,350 |
D/D |
15,000 |
40,756 |
|
- |
|
| Staple Peter D |
Director |
– • – |
2011-09-09 |
4 |
B |
$5.66 |
$28,439 |
D/D |
5,000 |
20,000 |
2.39 |
- |
|
| Vargas Thadd M |
Senior VP, BD |
• – – |
2011-09-08 |
4 |
OE |
$1.83 |
$32,780 |
D/D |
12,083 |
12,083 |
|
- |
|
| Schoeneck James A |
President and CEO |
• • – |
2011-08-23 |
4 |
B |
$5.04 |
$102,582 |
D/D |
20,000 |
20,000 |
2.81 |
- |
|
| Stern Julian N |
Director |
– • – |
2011-08-02 |
4 |
OE |
$5.80 |
$58,000 |
D/D |
10,000 |
193,333 |
|
- |
|
| Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2011-06-15 |
4 |
S |
$8.40 |
$11,627 |
D/D |
(1,385) |
1,778 |
|
- |
|
| Dawes Karen A |
Director |
– • – |
2011-06-14 |
4 |
B |
$8.23 |
$8,228 |
D/D |
1,000 |
6,000 |
2.39 |
- |
|
| Sweeney Michael Md |
CMO and VP, R&D |
• – – |
2011-06-14 |
4 |
S |
$8.18 |
$36,558 |
D/D |
(4,470) |
3,163 |
|
- |
|
246 Records found
|
|
Page 8 of 10 |
|
|
0.09 (8.57%) 
